There are currently 874 clinical trials in Indianapolis, Indiana looking for participants to engage in research studies. Trials are conducted at various facilities, including Indiana University, Indiana University Melvin and Bren Simon Cancer Center, Riley Hospital for Children and Indiana University Cancer Center. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Transcutaneous Vagus Nerve Stimulation (tcVNS) in JIA
Recruiting
The study is a multicenter, double-blind, sham-controlled trial to evaluate the safety and effectiveness of tcVNS on pain and inflammation associated with JIA. tcVNS is administered with a device that gives off mild electrical impulses through the skin to stimulate the vagus nerve. Part of the vagus nerve and its branches are located in the head and neck. For this study, the impulses will be administered in areas overlying the vagus nerve using a small electrode. The electrode helps to conduct t... Read More
Gender:
All
Ages:
Between 5 years and 18 years
Trial Updated:
05/23/2024
Locations: Indiana University, Indianapolis, Indiana
Conditions: Juvenile Idiopathic Arthritis (JIA)
Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)
Recruiting
The purpose of this study is to find out whether the study drug, LY3537982, is safe and effective in cancer patients who have a specific genetic mutation (KRAS G12C). Patients must have already received or were not able to tolerate the standard of care, except for specific groups who have not had cancer treatment. The study will last up to approximately 4 years.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/23/2024
Locations: Indiana Univ Melvin & Bren Simon Cancer Center, Indianapolis, Indiana +1 locations
Conditions: Carcinoma, Non-Small-Cell Lung, Endometrial Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Biliary Tract Neoplasms, Colorectal Neoplasms
Janus Kinase (JAK) Inhibitors to Preserve C-Peptide Production in New Onset Type 1 Diabetes (T1D)
Recruiting
A multi-center, placebo-controlled, double blind, 1:1:1 randomized control clinical trial testing two different JAK Inhibitors abrocitnib, ritlecitinib, and placebo in subjects with recent onset Stage 3 Type 1 Diabetes within 100 days of diagnosis.
Gender:
All
Ages:
Between 12 years and 35 years
Trial Updated:
05/23/2024
Locations: Indiana University, Indianapolis, Indiana
Conditions: Diabetes Mellitus, Type 1
A Trial to Evaluate the Efficacy and Safety of Different Doses of LEO 138559 in Adults With Moderate-to-severe Atopic Dermatitis
Recruiting
The purpose of this trial is to test different doses of the trial medicine (LEO 138559) at treating moderate to severe atopic dermatitis in adults. There will be 4 different doses, that will also be compared to a placebo (a dummy medicine that doesn't contain the active ingredient of LEO 138559). Each participant will be randomly assigned to one of the 4 doses of LEO 138559 or placebo. In all arms, injections of placebo may be used to mask the different doses. The trial will last up to 36 weeks... Read More
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
05/23/2024
Locations: LEO investigational site, Indianapolis, Indiana
Conditions: Atopic Dermatitis
Nonalcoholic Fatty Liver Disease (NAFLD) Database 3
Recruiting
The NAFLD Database 3 will enroll approximately 1500 adult patients and 750 pediatric patients suspected or known to have NAFLD or NASH-related cirrhosis. To elucidate, through the cooperative effort of a multidisciplinary and multicenter group of collaborators, the etiology, natural history, diagnosis, treatment, and prevention of NAFLD, and in particular its more severe form of NASH and its complications.
Gender:
All
Ages:
2 years and above
Trial Updated:
05/23/2024
Locations: Indiana University- Adults, Indianapolis, Indiana +1 locations
Conditions: Liver Diseases
A Master Protocol (LY900023) That Includes Several Clinical Trials of Drugs for Children and Young Adults With Cancer
Recruiting
The main purpose of the master is to help the research sites and sponsor carry out several clinical trials more efficiently by providing a common research protocol. Individual clinical trials under this master protocol define drug/disease-specific research goals and activities to test them. New studies will be added as new drugs emerge against different cancers. Participation in the trial will depend on how long the benefit lasts.
Gender:
All
Ages:
Between 1 year and 39 years
Trial Updated:
05/23/2024
Locations: Riley Hospital for Children, Indianapolis, Indiana
Conditions: Neoplasms, Child, Adolescent
Influence of Cooling Duration on Efficacy in Cardiac Arrest Patients
Recruiting
A multicenter, randomized, adaptive allocation clinical trial to determine if increasing durations of induced hypothermia are associated with an increasing rate of good neurological outcomes and to identify the optimal duration of induced hypothermia for neuroprotection in comatose survivors of cardiac arrest.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/23/2024
Locations: IU Health Methodist Hospital, Indianapolis, Indiana
Conditions: Cardiac Arrest, Out-Of-Hospital, Hypothermia, Induced, Hypoxia-Ischemia, Brain
A Study of the Effects of Camoteskimab in Adults With Moderate to Severe Atopic Dermatitis
Recruiting
This is a Phase 2a, multicenter, randomized, double-blind, placebo-controlled study with an open-label extension to evaluate the efficacy and safety of camoteskimab in adults with moderate to severe AD.
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
05/22/2024
Locations: Dawes Fretzin Clinical Research, Indianapolis, Indiana
Conditions: Atopic Dermatitis, Atopic, Dermatitis, Dermatologic Disease, Eczema, Eczema Atopic Dermatitis, Eczema, Atopic
Long Term, Extension Study of the Safety and Efficacy of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type
Recruiting
This is an extension study of the Phase 3 Studies 15-AVP-786-301, 15-AVP-786-302, and 17-AVP-786-305, which also allows participants from the Phase 2 Study 12-AVR-131 to be included.
Gender:
All
Ages:
Between 50 years and 90 years
Trial Updated:
05/22/2024
Locations: Indiana University School of Medicine, Indianapolis, Indiana +1 locations
Conditions: Agitation in Patients With Dementia of the Alzheimer's Type
Olanzapine Versus Megestrol Acetate for the Treatment of Loss of Appetite Among Advanced Cancer Patients
Recruiting
This phase III trial compares the effects of olanzapine versus megestrol acetate in treating loss of appetite in patients with cancer that has spread to other places in the body (advanced). Olanzapine may stimulate and increase appetite. This study aims to find out if olanzapine is better than the usual approach (megestrol acetate) for stimulating appetite and preventing weight loss.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/22/2024
Locations: Saint Catherine Hospital, Indianapolis, Indiana
Conditions: Advanced Malignant Solid Neoplasm, Anorexia, Hematopoietic and Lymphoid Cell Neoplasm
Testing the Use of BRAF-Targeted Therapy After Surgery and Usual Chemotherapy for BRAF-Mutated Colon Cancer
Recruiting
This phase II/III trial compares treatment with encorafenib and cetuximab to usual care (patient observation) for reducing the chance of cancer recurrence after standard surgery and chemotherapy in patients with BRAF-mutated stage IIB-III colon cancer. Encorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Cetuximab is in a class of medications called monoclonal antibodies. It binds to a protein called EGFR, which is found on some types of tumor ce... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
05/22/2024
Locations: Saint Catherine Hospital, Indianapolis, Indiana
Conditions: Colon Adenocarcinoma, Microsatellite Stable Colon Carcinoma, Stage IIB Colon Cancer AJCC v8, Stage IIC Colon Cancer AJCC v8, Stage III Colon Cancer AJCC v8
Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell Lymphoma
Recruiting
This phase III trial tests whether continuous or intermittent zanubrutinib after achieving a complete remission (CR) with rituximab works in older adult patients with mantle cell lymphoma (MCL) who have not received treatment in the past (previously untreated). Rituximab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. Zanubrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. When zanubrutinib is used... Read More
Gender:
All
Ages:
60 years and above
Trial Updated:
05/22/2024
Locations: Saint Catherine Hospital, Indianapolis, Indiana
Conditions: Mantle Cell Lymphoma